NorthWest Biotherapeutics Inc (NWBO)

[Virgilio]

the distinct possibility that PFS/OS endpoints may not have been achieved, focus is upon the long tail

I have the same fear at this point. But those are the study endpoints, I doubt that a long tail will be enough for approval. My fear is that if the primary and secondary endpoints are not reached, further trials would be required.